WAB Options Flip Bullish After Q3 Print

WAB reported Q3 results on Tuesday and the options market moved fast: the put/call ratio collapsed to 0.44, nearly three standard deviations below its 20-day average of 0.70, the most call-heavy reading the stock has seen in at least a year.

That shift is sharp and recent. Through all of September and into early October, the PCR ran consistently above 0.89, reflecting defensive positioning ahead of the print. It has unwound in two sessions. Tuesday and Monday alone took the ratio from above 0.70 to 0.44, the 52-week low is 0.25, so there is room further in that direction, but the move already represents an unusual re-rating of sentiment. The borrow market has not reacted with the same urgency: availability is vast, with roughly 94 shares available to lend for every one currently borrowed, and borrowing cost dropped to 0.43% from 0.54% earlier in the week. Short interest edged down 0.2% over the week to 2.0% of the free float, continuing a gradual decline from a 30-day high of around 2.1%. There is no short-side pressure of any consequence here.

The Street's reaction to the print is consistent with the options shift. Most analysts held their ratings and targets roughly where they were. Citigroup's Buy target remains at $338 after a modest trim earlier in October, and Morgan Stanley's Overweight target of $355 has been in place since July. JP Morgan is the outlier, sitting at Neutral with a $320 target, below the current price of $283. The consensus mean target of $331 implies about 17% upside from here, and the forward earnings picture has been improving: the 12-month forward EPS growth score ranks in the 76th percentile of the universe. EV/EBITDA has drifted lower over the past month, down about 0.3 turns to 16.3x, which is a modest de-rating rather than a sharp one. The valuation is not cheap by industrial standards, but the bear case, centred on a global industrial slowdown and domestic railcar weakness, has not visibly gained traction in analyst revisions since July's earnings-driven upgrade cycle.

Among peers, WAB's week was in line: the stock fell 1.1% against a median decline of roughly 1.5% across its closest correlated names. MLI was the outlier on the downside, dropping 7.6% on the week. PCAR and ATMU were the few names in positive territory, up 1.9% and 2.3% respectively. WAB neither led nor lagged in any meaningful way, which is notable given it just printed results while most peers did not.

CEO Rafael Santana sold roughly 1,900 shares across October 5 and 6 at prices between $287 and $294, totalling around $520,000. All transactions were under a pre-arranged 10b5-1 plan, so they carry limited signalling value as expressions of conviction. The 90-day net insider position is negative at roughly $7.4 million sold, but the 10b5-1 framing applies to the bulk of that. FMR LLC remains the largest institutional holder at 10.9% of shares, and its stake grew by around 2 million shares in the quarter to September 30. No 13D activists are on the register; all major holders filed under Schedule 13G, the passive designation.

Wikipedia attention spiked to a z-score of 4.6 against WAB's own 90-day history in late September, an unusual level of retail interest. The timing preceded the earnings date by several weeks, and there are no measured alt-data leads for this company, so the signal is colour rather than a directional read on fundamentals.

The Q3 report is now out and no next earnings date has been set yet. The number to track from here is whether the PCR holds near the low end of its range or reverts toward the 0.70 average, and whether the analyst community begins revising the EPS outlook that the July print triggered upward.